ORICNasdaqPharmaceutical PreparationsFiscal year ends December 31
Oric Pharmaceuticals, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026
$12.72+0.37 (+3.00%)
Close on Oct 19, 2026
- Market cap
- $1.37B
- P/E (TTM)
- –
- Dividend yield
- –
Margins need revenue and profit figures
This company does not report the lines needed to calculate margins.
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|
Returns and balance sheet
9 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2017 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | -73.8% | -41.3% | |
| Return on assets | – | -37.5% | -37.9% | |
| Current ratio | – | 32.96 | 14.13 | |
| Diluted shares | – | 22M | 88M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Oric Pharmaceuticals generated $444.00M from operations and spent $5.77M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$444.00M
Used
$5.77M
Capital expenditure$5.77M100%Dividends$00%Share buybacks$00%
DuPont needs revenue, assets and equity
This company does not report all three for consecutive years.
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
3of 6 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$129.47M
- Cash generatingOperating cash flow above zero-$110.97M
- Return on assets improvedROA up on the prior year-50.7% → -47.2%
- Earnings backed by cashOperating cash flow above net income-$110.97M vs -$129.47M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose10.56 → 14.13
- No dilutionShare count did not rise70M → 88M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose– → –